Compare Recursion Pharmaceuticals Inc (RXRX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Energy Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Energy Select Sector SPDR Fund trades at $58.46. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XLE | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | — |
52-Week High | $6.79 | $62.57 |
52-Week Low | $2.84 | $42.12 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
XLE is trading at $57.96, up 0.49% with a bullish technical signal supported by strong moving average indicators. The energy ETF benefits from record refiner margins and geopolitical tensions driving oil prices higher. Recent news highlights XLE as a top-performing sector SPDR with 21% year-to-date gains, though RSI levels suggest potential overbought conditions near-term.
The energy sector outlook remains positive with Q2 earnings growth expectations and strong institutional support, though investors face risks from oil price volatility and geopolitical uncertainty. Technical resistance at $58-59 may limit immediate upside, while sector rotation and clean energy competition present longer-term considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
